RWM
BIO icon

Rialto Wealth Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Rialto Wealth Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$279 Sell
1
-1
-50% -$288 ﹤0.01% 1551
2025
Q4 		$606 Hold
2
– – ﹤0.01% 1180
2025
Q3 		$561 Buy
+2
New +$544 ﹤0.01% 1165

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Rialto Wealth Management's BIO Position: Q1 2026 in Review

Rialto Wealth Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 50% in Q1 2026, selling an estimated $288 and leaving 1 share worth $279. The position accounts for ﹤0.01% of the portfolio, ranked #1551.

Rialto Wealth Management first reported a position in BIO in Q3 2025 and has held it in 3 quarters since. The position peaked at $606 in Q4 2025. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • Rialto Wealth Management held 1 share of Bio-Rad Laboratories Class A worth $279 as of Q1 2026.
  • Rialto Wealth Management sold 1 Bio-Rad Laboratories Class A share in Q1 2026, an estimated $288.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Rialto Wealth Management's portfolio in Q1 2026, its #1551 holding.
  • Rialto Wealth Management first reported a position in Bio-Rad Laboratories Class A in Q3 2025 and has held it in 3 quarters since.
  • Rialto Wealth Management's Bio-Rad Laboratories Class A position peaked at $606 in Q4 2025.
  • 391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Rialto Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.